Pharvaris NV reports results for the quarter ended June 30 - Earnings Summary

Pharvaris NV

12/08/2025 22:00

Pharvaris NV PHVS.OQ reported a quarterly adjusted loss of 83 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -55 cents.  The mean expectation of nine analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from -83 cents to -71 cents per share.

Reported revenue was zero​; analysts expected zero.

Pharvaris NV's reported EPS for the quarter was a loss of 83 cents​.

The company reported a quarterly loss of €45.48 million.

Pharvaris NV shares had risen by 18.4% this quarter and gained 8.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Pharvaris NV is $30.00, about 30.5% above its last closing price of $20.84

This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.77
-0.83
Missed
Mar. 31 2025
-0.76
-0.85
Missed
Dec. 31 2024
-0.72
-0.64
Beat
Sep. 30 2024
-0.61
-0.77
Missed